Clinical Trial Update: Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients [Phase 2]

View source ↗

Summary

A National Institute of Allergy and Infectious Diseases–sponsored Phase 2 trial evaluated immune suppression using alemtuzumab and tacrolimus in liver transplan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Disease
• Liver Transplantation

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Tacrolimus (Tacrolimus)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Liver Disease, Liver Transplantation | Phase 2 | Status: COMPLETED | Results posted: 2012-04-05